Press Releases

Tecarfarin, a novel therapy designed for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with End Stage Renal Disease and Atrial Fibrillation, may be a new treatment option for this underserved patient population PONTE VEDRA, Fla., March 9, 2023 — Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) a biopharmaceutical company focused on developing tecarfarin, a clinical-stage novel cardiorenal therapy with orphan drug and Fast Track designations, recognizes National Kidney Month throughout the month

PONTE VEDRA, Fla., Feb. 8, 2023 — Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) a biopharmaceutical company focused on developing tecarfarin, a clinical-stage novel cardiorenal therapy with orphan drug and Fast Track designations, today announced that Chairman and Chief Executive Officer, Quang Pham, and other Cadrenal team members will ring the Nasdaq Stock Market closing bell on Wednesday, February 8, 2023. “We are excited to ring the Nasdaq closing bell to commemorate our recent IPO and announcement

PONTE VEDRA, Fla., Feb. 6, 2023 — Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company focused on developing tecarfarin, a clinical-stage novel cardiorenal therapy with orphan drug and Fast Track designations, today announced that Chairman and Chief Executive Officer, Quang Pham, is available for one-on-one meetings at the BIO CEO & Investor Conference taking place at the New York Marriott Marquis Times Square on February 6-8, 2023. Meetings with conference attendees can be scheduled through

PONTE VEDRA, Fla., Feb. 1, 2023 — Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) a biopharmaceutical company focused on developing tecarfarin, a clinical-stage novel cardiorenal therapy with orphan drug and Fast Track designations, announced today the formation of its Scientific Advisory Board (SAB) in support of the development of tecarfarin for the prevention of systemic thromboembolism, more commonly referred to as blood clots, of cardiac origin in patients with end-stage renal disease and atrial fibrillation (ESRD +

Cadrenal Therapeutics (Nasdaq: CVKD) Announces Closing of Initial Public Offering PONTE VEDRA, Fla., Jan. 24, 2023 /PRNewswire/ — Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company focused on developing tecarfarin, a clinical-stage novel cardiorenal therapy with orphan drug indication, today announced the closing of its initial public offering of 1,400,000 shares of common stock at a public offering price of $5.00 per share for gross proceeds of $7,000,000, before deducting underwriting discounts and estimated offering expenses. In addition, the Company has granted